



NEW COUNTRY MANAGER BRINGS SIGNIFICANT BUSINESS LEADERSHIP AND HEALTHCARE EXPERTISE TO MITSUBISHI TANABE PHARMA CANADA, INC.

TORONTO, September 28, 2018 – Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced the appointment of Andrew Zylak as Canada Country Manager. In this executive leadership role, Zylak will oversee the operations and growth of the business in Canada and bringing new treatments to the market for unmet medical needs including rare diseases.

“We are fortunate to have someone of Andrew’s caliber and experience to lead our company into Canada. His impressive pharmaceutical experience will be pivotal as we continue to expand the global reach of our business,” said Atsushi Fujimoto, President, MTP-CA. “Andrew has a proven track record of execution across his previous roles with global pharmaceutical companies and he will be a key leader in advancing our company in Canada.”

MTP-CA is at an important time entering the Canadian marketplace. In March of 2018, MTPA established the subsidiary MTP-CA to facilitate bringing new treatments to Canadian patients. On April 9, 2018, Health Canada accepted the company’s New Drug Submission (NDS) for edaravone, an intravenous treatment option for amyotrophic lateral sclerosis (ALS), a rapidly progressive neurological disease,¹ and also informed the company that the NDS had been granted Priority Review.

“MTP-CA provides one of those rare opportunities to truly bring new solutions to disease areas with limited treatments, and I couldn’t be more honoured to have been chosen to lead the Canadian company,” Andrew Zylak said. “The opportunity ahead is vast and we must focus and continue to evolve and grow in Canada. A big part of my job is to build the organization to enable us to bring innovative medicines to Canadians quickly.”

Zylak has more than 20 years of experience in the pharmaceutical industry, spanning across numerous roles and therapeutic areas. Prior to joining MTP-CA, he served as head of the Canadian neuroscience business unit at Allergan. Zylak also was Vice President of the Cardiovascular and Metabolic Business Unit at AstraZeneca Canada. Throughout his career, Zylak also has held a series of progressive positions in sales, sales management, training, marketing management and senior leadership, including significant launch and specialty care experience.

About Mitsubishi Tanabe Pharma Canada, Inc.

Based in Toronto, Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) with a goal to provide therapies for some of the most difficult-to-treat diseases, including ALS.

About Mitsubishi Tanabe Pharma America, Inc.

Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTPA is dedicated to delivering innovative products that address the unmet medical needs of patients in North America. It was established by MTPC to commercialize approved pharmaceutical products in North America with plans to expand its product line through collaborations with partners. For more information, please visit www.mt-pharma-america.com.

-ends-

Media inquiries:

Debbie Etchison

908-340-8578

Debbie_Etchison@mt-pharma-us.com

¹ National Institute of Neurological Disorders and Stroke. Amyotrophic Lateral Sclerosis (ALS) Information Page. <https://www.ninds.nih.gov/disorders/all-disorders/amyotrophic-lateral-sclerosis-als-information-page>. Accessed March 2018.